Website: [www.locus-bio.com](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttp-253A-252F-252Fwww.locus-2Dbio.com-26data-3D01-257C01-257Cjoseph.nixon-2540locus-2Dbio.com-257C47e01452c96e4eee23b208d737ca5c3f-257C16b58b1823bc474d8293aed343cf729f-257C0-26sdata-3DU3XBt0UdbRBoj6fBCQnOtg3864Z8bJ4BcSZ4IzePi4Q-253D-26reserved-3D0%26d%3DDwMFAg%26c%3DQbuapHRvbn0JdC8vTVkPHg%26r%3DBRvmOOkD1Z5gYGCwq77Jdw%26m%3DDhWSeLxO8MO2VbhjVACXZiP-udL4GX_B-PhjlLXAtZU%26s%3D3b05G5dqRroGq5HtVzEuBWNthuE2o-D8-sG7eeoi5Vg%26e%3D&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=lPI05zxjG51SLlmyb%2BEMdrpRlefRcSP4tHzFiJoGX4E%3D&reserved=0)

**25 Word Summary**

Locus Biosciences is a clinical-stage biotechnology company developing engineered bacteriophage products to address critical unmet medical needs in bacterial infections and immunology.

**50 Word Summary**

Locus Biosciences is a clinical-stage biotechnology company developing engineered bacteriophage products to address critical unmet medical needs in bacterial infections and immunology. The LOCUS platform combines predictive artificial intelligence and automated robotics to deliver optimized precision phage therapies that specifically kill target pathogens while leaving non-target bacteria (i.e., the rest of the patient’s microbiome) unaffected.

**100 Word Summary**

Locus Biosciences is a clinical-stage biotechnology company developing engineered bacteriophage products to address critical unmet medical needs in bacterial infections and immunology. The LOCUS platform combines predictive artificial intelligence and automated robotics to deliver optimized precision phage therapies that specifically kill target pathogens while leaving non-target bacteria (i.e., the rest of the patient’s microbiome) unaffected. Locus has strong backing from partners, having signed contracts with BARDA that could yield up to $85 million in revenue to Locus and with CARB-X for up to $12 million. The company recently completed the open-label portion of a Phase 2 trial assessing LBP-EC01 for the treatment of uncomplicated UTIs caused by drug resistant *E. coli*.

**Highlights of Company Achievements:**

* Locus completed open-label portion of the two-part Phase 2 ELIMINATE trial for LBP-EC01, a bacteriophage product for urinary tract infections caused by antimicrobial resistant (AMR) and multi-drug resistant (MDR) *E. coli* bacteria.
* Locus raised a [$35 million Series B](https://www.locus-bio.com/locus-biosciences-announces-35-million-financing/) financing round.
* Contract with the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to fund up to [$12.5 million of a $14.8 million program](https://carb-x.org/carb-x-news/carb-x-is-funding-locus-biosciences-to-develop-an-innovative-crispr-cas-3-enhanced-bacteriophage-targeting-antibiotic-resistant-klebsiella-pneumoniae-infections/) for development of LBP-KP01, an engineered bacteriophage product targeting the bacterial pathogen *Klebsiella pneumoniae* (*K. pneumoniae*) through Phase 1 clinical development.
* Contract with the Biomedical Advanced Research and Development Authority (BARDA) to co-fund development of LBP-EC01, an engineered bacteriophage product that will target *Escherichia coli* (*E. coli*) bacteria causing recurrent urinary tract infections (UTIs). The contract provided up to [$77 million in funding to Locus as part of a $144 million program](https://www.prnewswire.com/news-releases/locus-biosciences-signs-contract-with-barda-to-advance-144-million-precision-medicine-program-to-develop-lbp-ec01-a-crphage-product-301141814.html) (since expanded to $85 million) to support Phase 2 and Phase 3 clinical trials and other activities required to seek marketing approval from the U.S. Food and Drug Administration (FDA) for LBP-EC01.
* Executed an [$818m collaboration](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fwww.locus-2D2Dbio.com-5Fpress-2D2Dreleases-5F-2526d-253DDwMFAg-2526c-253DQbuapHRvbn0JdC8vTVkPHg-2526r-253DBRvmOOkD1Z5gYGCwq77Jdw-2526m-253DDhWSeLxO8MO2VbhjVACXZiP-2DudL4GX-5FB-2DPhjlLXAtZU-2526s-253DbsAGDDCvwVW5qdv4aLmmnqaH7gnICs5gYNRdDr4HQ18-2526e-253D-26data-3D01-257C01-257Cdave-2540locus-2Dbio.com-257C38b9fff333a5480190e308d746e93cdc-257C16b58b1823bc474d8293aed343cf729f-257C0-26sdata-3DThytWRRfPY3hMKLmz6wyxXQP-252FE02-252F6mftbQ-252FyrxOt1M-253D-26reserved-3D0%26d%3DDwMGaQ%26c%3DQbuapHRvbn0JdC8vTVkPHg%26r%3DBRvmOOkD1Z5gYGCwq77Jdw%26m%3Diz0IoS5fwMuJvdaxrUfN3ErCQi5j9DZV6lq7DYh_CB0%26s%3D4AGXUkKZruuoNPqKN1FH11BZuSQAOL-tGVoGSkNAO6Y%26e%3D&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=cGM50I5beJYclE6e3gmZ3Z3ywYdWiy7jtpgdolN5dR0%3D&reserved=0) ($20m upfront) with Johnson & Johnson on company’s second and third pipeline assets in January 2019. Collaboration ran through mid-2023, producing two clinical candidates, before J&J strategically exited the infectious diseases therapeutic area
* Selected by FierceBiotech for the [2019 Fierce 15](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fwww.fiercebiotech.com-5Fspecial-2D2Dreport-5Ffiercebiotech-2D2Ds-2D2D2019-2D2Dfierce-2D2D15-2526d-253DDwMFAg-2526c-253DQbuapHRvbn0JdC8vTVkPHg-2526r-253DBRvmOOkD1Z5gYGCwq77Jdw-2526m-253DDhWSeLxO8MO2VbhjVACXZiP-2DudL4GX-5FB-2DPhjlLXAtZU-2526s-253Dk0ecH2pQiecLTuDsPVjXN1xAd-5F2zzT0eoatrd8ww3dg-2526e-253D-26data-3D01-257C01-257Cdave-2540locus-2Dbio.com-257C38b9fff333a5480190e308d746e93cdc-257C16b58b1823bc474d8293aed343cf729f-257C0-26sdata-3DfWq55fABDAfqzlUz9EW5uOpOdrQmpMsxxt9fl5bto-252Fg-253D-26reserved-3D0%26d%3DDwMGaQ%26c%3DQbuapHRvbn0JdC8vTVkPHg%26r%3DBRvmOOkD1Z5gYGCwq77Jdw%26m%3Diz0IoS5fwMuJvdaxrUfN3ErCQi5j9DZV6lq7DYh_CB0%26s%3DQ66kdDUIKq0TUJvGUpFZnsGh6wxPMluIJbpI9FLPxL0%26e%3D&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=tsa0%2F%2B6mTvt5WvS%2BwBcr5NsvHgIOle6AyD6RWdpw0Lg%3D&reserved=0) which recognizes the best emerging biotechnology companies in the US and Europe and by CNBC for its [Upstart 100](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.cnbc.com%2F2019%2F11%2F12%2F100-of-the-worlds-most-promising-start-ups-to-watch-in-2019.html&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=HlRzgLT6e0O9Y9pgY8iZ8TbXHVcC6gQNj%2FOnkOsc4%2Fo%3D&reserved=0) list of the 100 most promising pre-Series B startups in the world
* Completed construction of cGMP manufacturing facility in May 2019 in Research Triangle Park, NC to produce Phase 2 to commercial scale material for its pipeline assets
* [Acquired assets of EpiBiome](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fwww.locus-2D2Dbio.com-5Flocus-2D2Dbiosciences-2D2Dacquires-2D2Depibiomes-2D2Dhigh-2D2Dthroughput-2D2Ddiscovery-2D2Dplatform-2D2Dto-2D2Dcreate-2D2Dthe-2D2Dworlds-2D2Dleading-2D2Dcrispr-2D2Dengineered-2D2Dbacteriophage-2D2Dcompany-5F-2526d-253DDwMFAg-2526c-253DQbuapHRvbn0JdC8vTVkPHg-2526r-253DBRvmOOkD1Z5gYGCwq77Jdw-2526m-253DDhWSeLxO8MO2VbhjVACXZiP-2DudL4GX-5FB-2DPhjlLXAtZU-2526s-253DVn58hDHG1thCii-5FjGvsnfcl1eb9vr58vdzOBkFBPN-2Dg-2526e-253D-26data-3D01-257C01-257Cdave-2540locus-2Dbio.com-257C38b9fff333a5480190e308d746e93cdc-257C16b58b1823bc474d8293aed343cf729f-257C0-26sdata-3DfXshBJ7jR-252F0xq7E-252B-252FhP3yc5w8nnxvZX4bri362s3OsQ-253D-26reserved-3D0%26d%3DDwMGaQ%26c%3DQbuapHRvbn0JdC8vTVkPHg%26r%3DBRvmOOkD1Z5gYGCwq77Jdw%26m%3Diz0IoS5fwMuJvdaxrUfN3ErCQi5j9DZV6lq7DYh_CB0%26s%3DQGvzO4XcFnkUYBzflI97ew0d7Npp74zSjhAFA-ywuzY%26e%3D&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=%2FglLaVOOcml%2BL2F26vHyLxzCXht2ToHSYC0L3SudPpk%3D&reserved=0) in July 2018 to add automated robotics and high-throughput screening of bacteriophage to the Locus synthetic biology platform
* Raised [$19m Series-A](https://nam10.safelinks.protection.outlook.com/?url=https%3A%2F%2Furldefense.proofpoint.com%2Fv2%2Furl%3Fu%3Dhttps-3A__nam01.safelinks.protection.outlook.com_-3Furl-3Dhttps-253A-252F-252Furldefense.proofpoint.com-252Fv2-252Furl-253Fu-253Dhttps-2D3A-5F-5Fwww.locus-2D2Dbio.com-5Flocus-2D2Dbiosciences-2D2Dcloses-2D2D19-2D2Dmillion-2D2Dseries-2D2Da-2D2Dled-2D2Dby-2D2Dartis-2D2Dventures-2D2Dfor-2D2Dcrispr-2D2Dcas3-2D2Dantimicrobials-5F-2526d-253DDwMFAg-2526c-253DQbuapHRvbn0JdC8vTVkPHg-2526r-253DBRvmOOkD1Z5gYGCwq77Jdw-2526m-253DDhWSeLxO8MO2VbhjVACXZiP-2DudL4GX-5FB-2DPhjlLXAtZU-2526s-253Dkkr4bDrAROdKYG1uZgO7UaqfOoPixvFyQ6nKjjk287E-2526e-253D-26data-3D01-257C01-257Cdave-2540locus-2Dbio.com-257C38b9fff333a5480190e308d746e93cdc-257C16b58b1823bc474d8293aed343cf729f-257C0-26sdata-3DkPsVYvGkCuveYy2Ogc5bF6Q1flsYqkIguXKdUuqpVWk-253D-26reserved-3D0%26d%3DDwMGaQ%26c%3DQbuapHRvbn0JdC8vTVkPHg%26r%3DBRvmOOkD1Z5gYGCwq77Jdw%26m%3Diz0IoS5fwMuJvdaxrUfN3ErCQi5j9DZV6lq7DYh_CB0%26s%3DqUGeO-9vJ2M7OPJ0h4UMyMOIJOiuFhNBo8ofgBKWnNM%26e%3D&data=01%7C01%7Cjoseph.nixon%40locus-bio.com%7Cb658034986174c57194108d7917b5843%7C16b58b1823bc474d8293aed343cf729f%7C0&sdata=WEKdJgvpu0EnVcULxYqBKK4tuAqBB1hGs73OJAF%2B78U%3D&reserved=0) funding round in September of 2017 led by ARTIS Ventures & Tencent Holdings